Filtered By:
Condition: Atrial Fibrillation
Drug: Pradaxa
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 1248 results found since Jan 2013.
Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation
Conclusions: A linear relationship was found between Temp-CLtotal of dabigatran and CLcr of patients. Depending on CLxr of patients, we recommend 4 different dosages of dabigatran etexilate to obtain Ctrough of dabigatran at approximately 70 ng/mL.
Source: Therapeutic Drug Monitoring - November 17, 2016 Category: Drugs & Pharmacology Tags: Original Article Source Type: research
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
This article reviews and highlights real and perceived implications of VKAs for the prevention of stroke in patients with non-valvular AF, with specific reference to their strengths and weaknesses compared with DOACs.
Source: Journal of Thrombosis and Thrombolysis - November 27, 2016 Category: Hematology Source Type: research
Pilot of a Computerised Antithrombotic Risk Assessment Tool Version 2 (CARATV2.0) for stroke prevention in atrial fibrillation.
CONCLUSIONS: This decision support tool can help optimise the use of antithrombotic therapy in patients with AF by considering risk versus benefit profiles and rationalising treatment selection.
PMID: 28070883 [PubMed - as supplied by publisher]
Source: Cardiology Journal - January 9, 2017 Category: Cardiology Authors: Wang Y, Bajorek B Tags: Cardiol J Source Type: research
The gap between indicated and prescribed stroke prevention therapies in a high-risk geriatric population
ConclusionsThis data set suggests that 37% of eligible elderly LTC residents failed to receive recommended stroke prevention therapies.
Source: Journal of Interventional Cardiac Electrophysiology - January 15, 2017 Category: Cardiology Source Type: research
Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain.
CONCLUSIONS: All three direct anticoagulants are cost-effective against acenocoumarol. Dabigatran is economically dominant over rivaroxaban and apixaban in the Spanish setting, as it is more effective and cheaper.
PMID: 28272725 [PubMed - in process]
Source: Revista de Neurologia - March 9, 2017 Category: Neurology Authors: Monreal-Bosch M, Soulard S, Crespo C, Brand S, Kansal A Tags: Rev Neurol Source Type: research
Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation
This study aimed to (1) evaluate anticoagulation use after a major bleeding event on dabigatran or warfarin and (2) compare outcomes between patients discontinuing anticoagulation and those restarting dabigatran or warfarin. Methods This was...
Source: Evidence-Based Medicine - June 9, 2017 Category: Internal Medicine Authors: Smit, M. D., Van Gelder, I. C. Tags: Therapeutics/Prevention Source Type: research
Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011 –2016
We used Danish nationwide registries to examine temporal trends in the predicted stroke and bleeding risks (mean CHA2DS2-VASc and HAS-BLED scores per year, respectively) as well as the combination of selected stroke and bleeding risk factors per year among atrial fibrillation (AF) patients initiated for the first time between 2011 and 2016 on vitamin K antagonists (VKAs), dabigatran, rivaroxaban, or apixaban.
Source: Thrombosis Research - October 16, 2017 Category: Hematology Authors: Alexandar Dukanovic, Laila Staerk, Emil Loldrup Fosb øl, Kasper Gadsbøll, Gunnar Hilmar Gislason, Jonas Bjerring Olesen Tags: Full Length Article Source Type: research
Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study).
CONCLUSIONS: A mixed intervention, consisting of patient education and a simple calendar reminder of drug intake, is an effective strategy to improve dabigatran therapeutic adherence in patients with NVAF. The percentage of adherence with dabigatran was high.
PMID: 29384410 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 1, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
CONCLUSIONS: Non-persistence (treatment discontinuation or switch) with vitamin K antagonists was lower than with rivaroxaban and dabigatran in French primary care; however, non-persistence with the newest drug, apixaban, was similar to vitamin K antagonists. Larger studies with longer follow-up are needed to support these findings. This study is registered on ClinicalTrials.gov (NCT02488421).
PMID: 29398546 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - February 2, 2018 Category: Cardiology Authors: Collings SL, Vannier-Moreau V, Johnson ME, Stynes G, Lefèvre C, Maguire A, Asmar J, Bizouard G, Duhot D, Mouquet F, Fauchier L Tags: Arch Cardiovasc Dis Source Type: research
Intravenous thrombolysis in stroke patients taking novel oral anticoagulants: experience with the low-dose 0.6 mg/kg of recombinant tissue-type plasminogen activator. Case reports
In the last decade, the novel oral anticoagulant (NOAC) dabigatran (a direct thrombin inhibitor), rivaroxaban, apixaban and edoxaban (direct factor Xa inhibitors) have been approved for primary and secondary prevention of stroke in patients with atrial fibrillation (AF) [1]. Compared with vitamin k antagonists such as warfarin, the NOACs offer benefits in terms of efficacy, safety and convenience [2]. The only currently approved treatment for acute stroke with a class I recommendation and level A evidence is intravenous recombinant tissue-type plasminogen activator alteplase (IV rt-PA) [4].
Source: Journal of the Neurological Sciences - July 7, 2018 Category: Neurology Authors: Massimiliano Plastino, Domenico Bosco, Laura Giofr è, Dario Cristiano, Franco Galati, Paolo Postorino, Arturo Consoli, Antonietta Fava, Domenico Consoli Tags: Letter to the Editor Source Type: research
Idarucizumab-facilitated intravenous thrombolysis in acute ischemic stroke: A therapeutic strategy requiring further investigation
Although dabigatran does a better job reducing the risk of cardioembolic stroke than warfarin in patients with non-valvular atrial fibrillation, 0.92 –1.34% of dabigatran users still develop isch emic stroke [1]. The usage of warfarin (even at a suboptimal therapeutic level) increases the risk of hemorrhagic transformation (HT) after intravenous thrombolysis (IT) [2]; therefore, current guidelines advise against performing IT in patients receiv ing any direct oral anti-coagulant (DOAC), including dabigatran [3].
Source: Journal of the Neurological Sciences - September 13, 2018 Category: Neurology Authors: Hsiao Yu-Jen, Tsai Yi-Te, Li-Kai Tsai, Fang Chen-wen Tags: Letter to the Editor Source Type: research
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after PCI: An ancillary analysis from the RE-DUAL PCI trial
ConclusionDabigatran dual therapy reduced bleeding events irrespective of bleeding risk category and demonstrated similar efficacy regardless of stroke risk category when compared with warfarin triple therapy.
Source: American Heart Journal - March 4, 2019 Category: Cardiology Source Type: research
Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
CONCLUSIONS: Initiation of apixaban versus NOACs was more common among patients with increased age, higher bleeding risk and decreased renal function, whereas initiation of apixaban versus VKAs was more common among patients with lower bleeding risk and better renal function.
PMID: 31014991 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - April 19, 2019 Category: Cardiology Authors: Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy FX, Ricci L, Steg PG Tags: Arch Cardiovasc Dis Source Type: research
Idarucizumab for Intravenous Thrombolysis and Endovascular Thrombectomy in Acute Stroke: A Case Report
Non –vitamin K antagonist oral anticoagulants (NOACs), such as dabigatran, are widely used to prevent ischemic stroke in patients with nonvalvular atrial fibrillation. Nonetheless, stroke occurs in 1–2% of patients, and the use of NOACs may increase the bleeding risk for patients who are receiving a cute treatment of intravenous thrombolysis (IVT) or endovascular thrombectomy (EVT). Idarucizumab, a monoclonal antibody developed to bind dabigatran, has been proven safe and effective for patients with uncontrolled bleeding or for patients planning to receive emergent procedures.
Source: The Journal of Emergency Medicine - November 15, 2019 Category: Emergency Medicine Authors: Yu-Ting Lin, Yen-Jun Lai, Tzu-Hsien Lai Tags: Selected Topics: Neurological Emergencies Source Type: research
Risk of stroke and other thromboembolic complications after interruption of DOAC therapy compared with warfarin therapy in patients with atrial fibrillation: a retrospective cohort analysis
This study did not find a significant difference in the complication rate after interruption of DOAC therapy compared with interruption of warfarin therapy in hospitalized patients with a high risk of thromboembolism.
Source: Journal of Investigative Medicine - November 25, 2021 Category: Research Authors: Hellerman Itzhaki, M., Greenberg, N., Margalit, I., Shochat, T., Krause, I., Goldberg, E. Tags: Original research Source Type: research
